PROFILE
UPM's Staff Profile
PROF. MADYA DR. CHIA SUET LIN
HEAD OF LABORATORY
INSTITUTE OF BIOSCIENCE
suetlin@upm.edu.my
PROFESSIONAL
Dr. Eddie Chia obtained his BSc (Microbiology), MSc (Molecular Biology), and PhD (Medical Biotechnology) from Universiti Putra Malaysia. Currently, he is the head of laboratory for UPM-MAKNA Cancer Research Laboratory (CANRES), Institute of Bioscience, and also an Associate Professor in the Department of Microbiology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia. His research interest is in field of virology, specifically, Newcastle disease virus (NDV), as an oncolytic virus for the treatment of cancer. His research team is working on genetically modifying the virus to reduce its pathogenicity towards avian species and to enhance the oncolytic activities of the virus by inserting potential gene(s) into the viral genome.
NAME :
(Prof. Madya Dr.) CHIA SUET LIN
MANAGERIAL POSITION :
HEAD OF LABORATORY
ENTITY :
INSTITUTE OF BIOSCIENCE
PERMANENT POST :
ASSOCIATE PROFESSOR
ENTITY :
FACULTY OF BIOTECHNOLOGY AND BIOMOLECULAR SCIENCES
DOWNLOAD CURRICULUM VITAE (PDF)
FIELD OF SUPERVISION
BIOTHERAPEUTICS / CANCER BIOLOGY AND ONCOLOGY / MEDICAL BIOTECHNOLOGY / MICROBIOLOGY / MOLECULAR BIOLOGY AND GENETIC ENGINEERING / VACCINE AND THERAPEUTICS
EDUCATIONAL BACKGROUND
2012
Doctor of Philosophy (Medical Biotechnology)
2005
Master of Science (Molecular Biology)
2002
Bachelor of Science (Honours) Microbiology
1999
Diploma in Laboratory Technology
WORKING EXPERIENCE
2012
Senior Lecturer - Universiti Putra Malaysia
2004
Lecturer - Tunku Abdul Rahman college
PROJECT
2017
Translational development of oncolytic Newcastle Disease Virus for treatment of colorectal cancer
2015
Enhancing the therapeutic potential of rAF NDV cancer vaccine
2015
Mechanism of methicillin resistant Staphylococcus aureus biofilms degradation by phage display
2015
Rescue of a genetic engineered lentogenic NDV vaccine with enhanced immunogenic properties
2014
Investigating the behaviour of Lactococcus lactis M4 during interaction with human colon cancer cell line, SW620
2014
Developing a Nanoparticulate-Delivery System for Increased Therapeutic Delivery of Anticancer Drugs using Fluorescently Labelled Chitosan Nanoparticles
2014
Development of Nanodelivery Systems for Anti-Cancer Drugs
2013
Detection of Persistent Newcastle disease virus Infection in Various Cancer Cell Lines
2013
Global Transcriptomic Analysis of Colorectal Cancer Cells Persistently Infected with Newcastle Disease Virus
CONSULTANCY SERVICES
2016
Isolation and Identification of unknown bacteria from POME
COURSE ATTENDED
2016
Good Clinical Practice
RESEARCH AREA
Virology, Microbiology, Medical Biotechnology, Cancer Biology, Cancer virotherapy
PUBLICATION
2025
Natural chromones targeting autophagy signalling pathways as potential anticancer interventions: a systematic review
2025
Mechanism and Predictive Role of NUB1 Protein in Oestrogen Receptor Pathway of FEC-Treated Breast Cancer Patients
2025
Viral vectors: design and delivery for small RNA
2025
Translocating shRNA: a novel approach to RNA interference with Newcastle disease virus as viral vector
2024
In silico selection of aptamers against SARS-CoV-2
2024
Development of a recombinant non-replicating Newcastle disease virus
2024
A novel chromone-based as a potential inhibitor of ULK1 that modulates autophagy and induces apoptosis in colon cancer
2023
Discovery of a novel dual functional phenylpyrazole-styryl hybrid that induces apoptotic and autophagic cell death in bladder cancer cells
2022
The SARS-CoV-2 Variants and their Impacts
2022
Site-directed mutagenesis of the C-terminal of the Newcastle disease virus V protein
2021
Reduced pathogenicity of velogenic NDV strain AF22420-I via site-directed mutagenesis of V gene
2021
Development of a T7 RNA polymerase expressing cell line using lentivirus vectors for the recovery of recombinant Newcastle disease virus
2021
Persistent Newcastle disease virus infection in bladder cancer cells is associated with putative pro-survival and anti-viral transcriptomic changes
2020
Synthesis and in-vitro anti-cancer evaluations of multi-methoxylated asymmetrical diarylpentanoids as intrinsic apoptosis inducer against colorectal cancer
2020
An improved method for the rescue of of recombinant Newcastle disease virus
2020
In-Vitro and In-Silico Evaluations of Heterocyclic-Containing Diarylpentanoids as Bcl-2 Inhibitors Against LoVo Colorectal Cancer Cells
2019
V protein, the virulence factor across the family Paramyxoviridae: a review
2019
An improved method for the rescue of of recombinant Newcastle disease virus
2019
Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference
2018
Newcastle disease virus strain AF2240 as an oncolytic virus: A review
2017
Group B Adenovirus Enadenotucirev Infects Polarised Colorectal Cancer Cells Efficiently from the Basolateral Surface Expected to be Encountered During Intravenous Delivery to Treat Disseminated Cancer
2017
Oncolytic Group B Adenovirus Enadenotucirev Mediates Oncosislike Cell Death with Membrane Permeabilisation and Release of Inflammatory Mediators
2016
Prevalance of cephalosporin- and fluroquinolone-resistant Escherichia coli from faecal samples of felines and canines.